Exposure-response analysis of tezepelumab in patients with severe asthma to guide phase 3 dose selection
N. Ly (Mountain View, United States of America), Y. Zheng (Mountain View, United States of America), J. Griffiths (Gaithersburg, United States of America), R. Van Der Merwe (Cambridge, United Kingdom), B. Agoram (Mountain View, United States of America), L. Roskos (Gaithersburg, United States of America)
Source: International Congress 2018 – Asthma management
Session: Asthma management
Session type: Poster Discussion
Number: 1688
Disease area: Airway diseases
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
N. Ly (Mountain View, United States of America), Y. Zheng (Mountain View, United States of America), J. Griffiths (Gaithersburg, United States of America), R. Van Der Merwe (Cambridge, United Kingdom), B. Agoram (Mountain View, United States of America), L. Roskos (Gaithersburg, United States of America). Exposure-response analysis of tezepelumab in patients with severe asthma to guide phase 3 dose selection. 1688
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you: